NASHVILLE, Tenn., April 30,
2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a
global leader in supply chain solutions for cell & gene
therapies, today announced that the Company will report financial
results for the first quarter ended March
31, 2024 on Tuesday, May 7,
2024 after U.S. markets close.
In addition to the earnings release, a document titled "Cryoport
First Quarter 2024 in Review", providing a review of Cryoport's
financial and operational performance and a general business
update, will be issued at 4:05 p.m. ET on
Tuesday, May 7, 2024. The document is designed to be read in
advance of the questions and answers conference call and will be
accessible at
https://ir.cryoportinc.com/news-events/ir-calendar.
Cryoport management will host a conference call the same day at
5:00 p.m. ET. The conference call
will be in the format of a questions and answers session and will
address questions members of the investment community have
regarding the Company's reported results. A slide deck will
accompany the call.
Conference Call Information
Date:
|
Tuesday, May 7,
2024
|
Time:
|
5:00 p.m. ET
|
Dial-in
numbers:
|
1-888-886-7786
(U.S.), 1-416-764-8658 (International)
|
Confirmation
code:
|
Request the "Cryoport
Call" or Conference ID: 15315763
|
Live
webcast:
|
'Investor Relations'
section at www.cryoportinc.com or click here.
|
|
Please allow 10 minutes
prior to the call to visit this site to download and install any
necessary audio software.
|
The questions and answers call will be recorded and available
approximately three hours after completion of the live event in the
Investor Relations section of the Company's website at
www.cryoportinc.com for a limited time. To access the replay
of the questions and answers click here. A dial-in replay of the
call will also be available to those interested, until May 14, 2024. To access the replay, dial
1-844-512-2921 (United States) or
1-412-317-6671 (International) and enter replay entry code:
15315763 #.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply
chain solutions for cell & gene therapies that enable
manufacturers, contract manufacturers (CDMO's), contract research
organizations (CRO's), developers, and researchers to carry out
their respective business with certainty. We provide a broad array
of supply chain solutions for the life sciences industry. Through
our platform of critical products and solutions including advanced
temperature-controlled packaging, informatics, specialized
bio-logistics services, bio-storage, bio-services, and cryogenic
systems, we are "Enabling the Future of Medicine™"
worldwide, through our innovative systems, compliant procedures,
and agile approach to superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complimented by over
50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the
Netherlands, Portugal,
Germany, Japan, Australia, India, and China
For more information, visit www.cryoportinc.com or follow us on
LinkedIn at https://www.linkedin.com/company/cryoportinc or
@cryoport on X, formerly known as Twitter at
www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely
historical, including statements regarding the Company's
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to the
Company's industry, business, long-term growth prospects, including
the Company's belief that its clinical trials portfolio constitutes
a significant long-term revenue growth opportunity, plans,
strategies, acquisitions, future financial results and financial
condition, such as the Company's outlook and guidance for full year
2024 revenue and the related assumptions and factors expected to
drive revenue, projected growth trends in the markets in which the
Company operates, the Company's plans and expectations regarding
the launch of new products and services, such as the expected
timing and benefits of such products and services launches, the
Company's expectations about future benefits of its acquisitions,
the Company's anticipation about 2024 as a year of progressive
recovery in its business with stronger overall growth in the
Company's services business, the Company's expectations of the
stabilization of MVE Biological Solutions revenue into 2024, the
Company's plans to continue to build out its platform and broaden
its scope with the expectation to further expand its market leading
position in cell & gene therapy, and anticipated regulatory
filings or approvals with respect to the products of the Company's
clients. It is important to note that the Company's actual results
could differ materially from those in any such forward-looking
statements. Factors that could cause actual results to differ
materially include, but are not limited to, risks and uncertainties
associated with the effect of changing economic and geopolitical
conditions, supply chain constraints, inflationary pressures, the
effects of foreign currency fluctuations, trends in the products
markets, variations in the Company's cash flow, market acceptance
risks, and technical development risks. The Company's business
could be affected by other factors discussed in the Company's SEC
reports, including in the "Risk Factors" section of its most
recently filed periodic reports on Form 10-K and Form 10-Q, as well
as in its subsequent filings with the SEC. The forward-looking
statements contained in this press release speak only as of the
date hereof and the Company cautions investors not to place undue
reliance on these forward-looking statements. Except as required by
law, the Company disclaims any obligation, and does not undertake
to update or revise any forward-looking statements in this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-first-quarter-2024-financial-results-on-may-7-2024-302131216.html
SOURCE Cryoport, Inc.